Patents by Inventor Clemence Girardet

Clemence Girardet has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods and compositions for treating decreased cognitive ability
    Patent number: 11969460
    Abstract: Disclosed are methods and compositions for treating cognitive decline in subjects in need. More specifically, disclosed are methods of administrating exogenous adropin to subjects suffering from, or at risk of, cognitive decline. Also disclosed are subjects who would benefit from such treatment and pharmaceutical acceptable compositions comprising adropin, adropin34-76, and derivatives or variations thereof.
    Type: Grant
    Filed: June 4, 2019
    Date of Patent: April 30, 2024
    Assignees: Saint Louis University, U.S. Department of Veternas Affairs
    Inventors: Andrew Alistair Butler, Susan Farr, Clemence Girardet
  • METHOD AND COMPOSITIONS FOR TREATING DECREASED COGNITIVE ABILITY
    Publication number: 20220370566
    Abstract: Disclosed are methods and compositions for treating cognitive decline in subjects in need. More specifically, disclosed are methods of administrating exogenous adropin to subjects suffering from, or at risk of, cognitive decline including the aged and those suffering from traumatic brain injury. Also disclosed are subjects who would benefit from such treatment and pharmaceutical acceptable compositions comprising adropin, adropin34-76, and derivatives or variations thereof.
    Type: Application
    Filed: November 12, 2019
    Publication date: November 24, 2022
    Inventors: Andrew Alistair Butler, Susan Farr, Clemence Girardet
  • METHODS AND COMPOSITIONS FOR TREATING DECREASED COGNITIVE ABILITY
    Publication number: 20210252108
    Abstract: Disclosed are methods and compositions for treating cognitive decline in subjects in need. More specifically, disclosed are methods of administrating exogenous adropin to subjects suffering from, or at risk of, cognitive decline. Also disclosed are subjects who would benefit from such treatment and pharmaceutical acceptable compositions comprising adropin, adropin34-76, and derivatives or variations thereof.
    Type: Application
    Filed: June 4, 2019
    Publication date: August 19, 2021
    Inventors: Andrew Alistair Butler, Susan Farr, Clemence Girardet